Urolithiasis associated with the protease inhibitor indinavir

Urology

Volumn 50, Issue 4, 1997, Pages 513-518

  Bruce, R Grady ^a   Munch, Larry C ^b   Hoven, Ardis D ^b   Jerauld, Richard S ^b   Greenburg, Richard ^b   Porter, William H ^b   Rutter, Philip W ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE; INDINAVIR;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCIDENCE; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEINASE INHIBITION; STONE FORMATION; UROLITHIASIS;

ADULT; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY CALCULI; MALE; MIDDLE AGED;

EID: 0030845902     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00399-3     Document Type: Article

References (10)

1. Crixivan® package insert. Merck and Co., Inc.; U.S. Human Health, 1996.
2. CDC update: provisional public health service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 45: 468-472, 1996.
3. Chodakewitz J, Deutsch P, and Leavitt R: Preliminary evaluation of the long term safety and antiviral activity exerted by Crixivan (MK-639), an oral HIV protease inhibitor (abstract). 5th European Conference Abstracts: Clinical and Experimental Treatment of HIV, Copenhagen, 1995, p 7.
4. Gulick R, Mellors J, and Havlur D: Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) andlamivudine (3TC) (abstract). 3rd Conference on Retroviruses and Opportunistic Infections, Washington, 1996, p 162.
5. Massari F, Stazewski S, and Berry P: A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine-naïve patients (abstract). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, California, 1995, Abstract LB-6.
6. Mellors J, Steigbigel R, and Gulick R: Antiretroviral activity of the oral protease inhibitor, MK-639, in p24 antigenemic, HIV-infected patients with less than 500 CD4/cu mm (abstract). 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, California, 1995, p 235.
7. Sutherland SE, Reigle MD, Seftel AD, and Resnick MI: Protease inhibitors and urolithiasis. J Urol 158: 31-33, 1997.
8. Tashima KT, Horowitz JD, and Rosen S: Indinavir nephropathy. N Engl J Med 336: 138-140, 1997.
9. White DJ, and Nancollas GH: Triamterene and renal stone formation: the influence of triamterene and triamterene stones on calcium oxalate crystallization. Calcif Tissue Int 40: 79-84, 1987.
10. Watson RA, Ettinger B, Deshon GE Jr, Agee RE, and Oldroyd NO: Triamterene stone: advantage of cystallographic analysis. Urology 18: 238-240, 1981.